Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,406

The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.

2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors

Open access
Perkins, Rebecca B., Guido, Richard S., Castle, Philip E., Chelmow, David, Einstein, Mark H., Garcia, Francisco, Huh, Warner K., Kim, Jane J., Moscicki, Anna-Barbara, Nayar, Ritu, Saraiya, Mona, Sawaya, George F., Wentzensen, Nicolas, Schiffman, Mark · 2020 · Journal of Lower Genital Tract Disease

Abstract

Table: of ContentsA. EXECUTIVE SUMMARY Updated US consensus guidelines for management of cervical screening abnormalities are needed to accommodate the 3 available cervical screening strategies: primary human papillomavirus (HPV) screening, cotesting with HPV testing and cervical cytology, and cervical cytology alone. New data indicate that a patient's risk of developing cervical precancer or cancer can be estimated using current screening test results and previous screening test and biopsy results, while considering personal factors such as age and immunosuppression. Routine screening applies only to asymptomatic individuals who do not require surveillance for prior abnormal screening results. The 2012 consensus guidelines were the first to be based on the principle of equal management for equal risk, specifically, the risk of a patient developing cervical cancer, estimated by the surrogate end point of the 5-year risk of cervical intraepithelial neoplasia (CIN) grade 3 (CIN 3) or more severe diagnoses (CIN 3+), regardless of which test combinations yielded this risk level. Introduction of risk-based guidelines in 2012 was a conceptual breakthrough, but the recommendations retained a continued reliance on complicated algorithms and insufficiently incorporated screening history. With a more nuanced understanding of how previous results affect risk, and more variables to consider, the 2019 guidelines further align management recommendations with current understanding of HPV natural history and cervical carcinogenesis. More frequent surveillance, colposcopy, and treatment are recommended for patients at progressively higher risk, whereas those at lower risk can defer colposcopy, undergo follow-up at longer surveillance intervals, and, when at sufficiently low risk, return to routine screening. Clearly defined risk thresholds to guide management are designed to continue functioning appropriately when population-level prevalence of CIN 3+ decreases because of HPV vaccination and also as new screening and triage tests are introduced. The revised guidelines provide a framework for incorporating new data and technologies as ongoing incremental recommendation revisions, minimizing the time needed to implement changes that are beneficial to patient care. B. INTRODUCTION This is the fourth American Society of Colposcopy and Cervical Pathology (ASCCP)-sponsored consensus guidelines for management of cervical cancer screening abnormalities, after the original consensus conferences in 20011 and subsequent updates in 20062 and 2012.3 An interim guidance publication providing management recommendations for primary HPV screening was released in 2015.4This document updates and replaces all previous guidance. The key difference between 2019 guidelines and previous versions is the change from primarily test results–based algorithms (e.g., “Colposcopy is recommended for patients with HPV-positive atypical squamous cells of undetermined significance [ASC-US], low-grade squamous intraepithelial lesion [LSIL],” etc.) to primarily “risk-based” guidelines (e.g., “Colposcopy is recommended for any combination of history and current test results yielding a 4.0% or greater probability of finding CIN 3+,” etc.). See for of risk for combinations of current screening test results and screening history from a of more patients for more a at of risk are in the by The of risk to and in data from screening and those with abnormalities, can be by risk using to in and to a recommended to routine screening, surveillance with testing at or intervals, colposcopy, or of the be and of the abnormalities are using risk in and abnormalities are the consensus recommendations in are based on risk, not results. of colposcopy, or surveillance be based on a patient's risk of CIN 3+ by a combination of current results and history The current test results management recommendations on the history of test results. Colposcopy can be for HPV testing or cotesting at is recommended for patients with screening abnormalities HPV with low risk of CIN 3+ (e.g., low-grade abnormalities after a screening HPV test or 3) for treatment is treatment treatment was for patients with cytology in the 2012 this guidance is patients or defined as treatment biopsy CIN is when the risk of CIN 3+ is and is for those with between and treatment is for patients or with squamous intraepithelial lesion cytology and testing for HPV HPV and or patients with HPV-positive cytology regardless of HPV be when considering for patients with the of treatment on treatment is to treatment for (CIN or CIN 3) in the is recommended for in is to treatment for CIN based on recommendations for CIN or CIN 3 and (CIN primary HPV screening regardless of triage testing from the (e.g., testing from the is recommended because the those cytology for HPV or the risk for CIN 3 and cancer, (e.g., with is when cytology results are HPV or testing is and testing of the is not the patient to surveillance with HPV testi

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/lgt.0000000000000525

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 110 references

Cited by

See all 1,406

Metadata

Authors
Perkins, R. B., Guido, R. S., Castle, P. E., Chelmow, D., Einstein, M. H., Garcia, F., Huh, W. K., Kim, J. J., Moscicki, A.-B., Nayar, R., Saraiya, M., Sawaya, G. F., Wentzensen, N., & Schiffman, M.
Venue
Journal of Lower Genital Tract Disease
Published
2020-04
Volume
24
Issue
2
Pages
102-131
ISSN
  • 1089-2591 (ISSN-L)
  • 1526-0976
OpenAlex
W3015112546
Cited by
1,406
References
110
FWCI
104.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. https://app.cochat.ai/papers/10.1097/lgt.0000000000000525
The paper
Perkins, R. B., Guido, R. S., Castle, P. E., Chelmow, D., Einstein, M. H., Garcia, F., Huh, W. K., Kim, J. J., Moscicki, A.-B., Nayar, R., Saraiya, M., Sawaya, G. F., Wentzensen, N., & Schiffman, M. (2020). 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease. https://doi.org/10.1097/lgt.0000000000000525

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.